US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

Speaking in an interview on the sideline of the launch of the programme in Birnin Kebbi on Saturday, Dr Suwaiba Jadadi from ...

Nigeria striker Taiwo Awoniyi is currently preparing for life after football by enrolling in a Sporting Directorship course ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology ...

CHD is said to occur due to HDV, leading to cirrhosis and liver failure. Credit: Pixel-Shot/Shutterstock. Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers CAMBRIDGE, England--(BUSINESS WIRE)--SOLASCURE Ltd ...